Fabian Gerber of SIX Swiss Exchange, Switzerland's principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the presence of Roche, Novartis, Lonza and many others; explains why biotech companies are choosing to go public at later stages of development; and the advantages of the Swiss financial sector on which SIX Swiss Exchange traded companies can leverage.
In general, biotech and life science companies [that list in Switzerland] benefit from a strong peer group and are helped by the fact that the listing and maintenance requirements on the Swiss stock exchange are market-oriented and balance the needs of the companies as well as the investors
